{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:02:13Z","timestamp":1791194533649,"version":"4.1.0"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":6513,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1997,11]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Intra-arterial injection of radioactive Lipiodol has shown promising results in patients with hepatocellular carcinoma (HCC) and portal obstruction. The aim of this prospective, randomized trial was to compare the efficacy and tolerance of <jats:sup>131<\/jats:sup>I-labeled Lipiodol and chemoembolization for the treatment of patients with HCC. From September 1990 to September 1993, 142 patients (135 men, 7 women; age: 65 \u00b1 6.6 years) were randomly assigned to treatment groups and given either intra-arterial injections of <jats:sup>131<\/jats:sup>I-labeled Lipiodol (60 mCi; 2.2 GBq) (n = 73) or chemoembolization (70 mg cisplatin) (n = 69). Subsequent injections were given at 2, 5, 8, 12, and 18 months. Tumor response was assessed on the basis of tumor size and serum \u03b1-fetoprotein levels. Patient tolerance was assessed clinically and angiographically. Survival rate was the main end-point. A total of 129 patients (65 in the <jats:sup>131<\/jats:sup>I-labeled Lipiodol group and 64 in the chemoembolization group) were available for analysis; 13 were excluded, mainly because of portal vein thrombosis. The two groups were comparable. Actuarial survival curves were not significantly different between the two groups. Overall survival rates at 6 months, 1, 2, 3, and 4 years were 69%, 38%, 22%, 14%, and 10%, and 66%, 42%, 22%, 3%, and 0% in the <jats:sup>131<\/jats:sup>I-labeled Lipiodol and chemoembolization groups, respectively. Reduction in tumor size was similar for the two groups, with complete response in 1 and 0 patients and partial response in 15 and 16 patients in the <jats:sup>131<\/jats:sup>I-labeled Lipiodol and chemoembolization groups, respectively. Tolerance was significantly better in the <jats:sup>131<\/jats:sup>I- labeled Lipiodol group both clinically (3 severe side effects vs. 29 in the chemoembolization group; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001) and angiographically (1 arterial thrombosis vs. 10 in the chemoembolization group; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .01). In terms of patient survival and tumor response, radioactive <jats:sup>131<\/jats:sup>I-labeled Lipiodol and chemoembolization were equally effective in the treatment of HCC, but tolerance to <jats:sup>131<\/jats:sup>I-labeled Lipiodol was significantly better.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.510260511","type":"journal-article","created":{"date-parts":[[2004,7,27]],"date-time":"2004-07-27T23:18:37Z","timestamp":1090970317000},"page":"1156-1161","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma"],"prefix":"10.1097","volume":"26","author":[{"given":"J","family":"Raoul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Guyader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bretagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Heautot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Duvauferrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bourguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bekhechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y M","family":"Deugnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.510260511","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-199711000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:01:33Z","timestamp":1739203293000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-199711000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,11]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1997]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.510260511","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[1997,11]]}}}